By Trisha Gladd, Editor, Pharmaceutical Online and Bioresearch Online
Shabbir Dahod, president and CEO of TraceLink, has been working in the pharmaceutical industry for over 11 years, and in the last 30 years, has founded three companies prior to launching Tracelink. When asked how he comes up with the ideas that have brought him so much success, Dahod credits a very specific approach he learned about during the commencement speech at his wife’s college graduation. The speaker was the president of John Hancock at that time, and Dahod says he made a comment that sticks with him to this day. “He said what you need to do is look for connections and patterns from one segment to another,” says Dahod. “What it forces you to do is think a little bit more about what’s happening at the meta level. How could that pattern be applied somewhere else?”
By Dr. Miri Halperin Wernli, Actelion Pharmaceuticals and Dr. Boaz Ganor, Lauder School of Government, Diplomacy, and Strategy
Slowly and steadily, terrorism, like a malignant cancer, has entered our lives. What once was an occasional event on the other side of the world can no longer be ignored as someone else's problem. Terrorists, alone, in cells, or part of expanding international networks, are affecting the way we live, the way we think, and the way we do business. Government facilities, planes, trains, ships, oil refineries, and luxury locations have all taken the biggest and most publicized hits.
By Bruce McDuffee, Vaisala Life Science Division
If you’re in the business of manufacturing drugs, medical devices, nutraceuticals, manufacturing or importing any product in the United States that must comply with current Good Manufacturing Practice (cGMP), your facility will be inspected by the U.S. Food and Drug Administration (FDA).
By Darrick Niccum, senior global product manager-biotechnology, TSI Incorporated
The laser induced fluorescence signatures generated from environmental particles are complex. It is a challenging task to discriminate viable from non-viable particles that have fluorescence characteristics.
By Gary Partington, Walker Barrier Systems
Isolators have been around the Pharmaceutical Industry since the early 1980s and in the Nuclear Industry (glovebox technology) since the 1950s. The intent of isolators is to create an airtight barrier or enclosure around a piece of equipment or process which provides absolute separation between the operator and product.